All In Biotech

Drug Trial Radar · NCT07843381

Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease

A Prospective Cohort Study of Telitacicept Versus Conventional Immunosuppressive Agents in Primary Sjögren's Disease With Interstitial Lung Disease

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Sep 16, 2027

Study completion Nov 20, 2027

Sponsor

Lead sponsor
Peking University People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease

Conditions

  • Sjögren's Disease
  • Interstitial Lung Disease

Interventions

  • Telitacicept 160mgDrug

    The study duration was 24 weeks, with the experimental group receiving subcutaneous injections of Telitacicept once weekly for a total of 24 weeks.

  • Conventional treatmentDrug

    Conventional treatment with methylprednisolone (≤ 40 mg/day) and other immunosuppressive agents (including but not limited to cyclophosphamide, tacrolimus, sirolimus, cyclosporine, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, tripterygium glycosides, methotrexate, and sulfasalazine). Treatment restrictions: The use of immunosuppressants was limited to a maximum of three agents throughout the 24-week period, and dose adjustments from baseline were restricted to within 30%.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Forced Vital Capacity Percent Predicted at Week 24Time frame: At baseline and at week 12,24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Rheumatology and Immunology, Peking University People's Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.